Drugs & Targets FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC February 21, 2025Vol.51 No.07
White House RFK Jr. is confirmed, NCORP stops collecting data on sexual orientation, genderOne month in: Trump’s impact on oncology February 14, 2025Vol.51 No.06By Claire Marie Porter and Jacquelyn Cobb
Drugs & Targets FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma February 14, 2025Vol.51 No.06
Drugs & Targets FDA approves Gomekli for pediatric patients with neurofiromatosis type 1 February 14, 2025Vol.51 No.06
Black History MonthFreeIn the Archives Marsha Henderson: “You have to continue to push for what you think is the right thing for public health.”Preserving an oral history by the former FDA associate commissioner of women’s heath February 07, 2025Vol.51 No.05By Katie Goldberg
Drugs & Targets FDA grants orphan drug designation to MB-105 for CD5-targeted CAR T-cell therapy February 07, 2025Vol.51 No.05
White House Tracking Trump’s early impact on cancer policyResearch and care disrupted, NCI programs face unpredictable future January 31, 2025Vol.51 No.04By Paul Goldberg
Drugs & Targets FDA approves Enhertu as first HER2-directed therapy for breast cancer January 31, 2025Vol.51 No.04
Drugs & Targets FDA approves Grafapex as preparative regiment for allogeneic hematopoietic stem cell transplantation in AML or MDS January 31, 2025Vol.51 No.04
